Why hormones protect against large bowel cancer: Old ideas, new evidence

Advances in Experimental Medicine and Biology

Volumn 617, Issue , 2008, Pages 259-269

  Newcomb, Polly A ^a   Pocobelli, Gaia ^a   Chia, Victoria ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN PLUS MEDROXYPROGESTERONE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; UNCLASSIFIED DRUG;

CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; HORMONE ACTION; HUMAN; LARGE INTESTINE CANCER; MORBIDITY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; ANIMAL; COLORECTAL TUMOR; ESTROGEN THERAPY; FEMALE; MALE; REVIEW; RISK FACTOR;

ANIMALS; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 46749097969     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69080-3_24     Document Type: Conference Paper

References (65)

1. Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 125-34.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Public-Use, Nov 2005 Sub (1973-2003 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
3. McMichael AJ, Potter JD (1983) Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal diseases? Am J Epidemiol 118: 620-7.
4. Chlebowski R, Wactawski-Wende J, Ritenbaugh C, et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350: 991-1004.
5. Fraumeni JF Jr., Lloyd JW, Smith EM, et al (1969) Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 42: 455-68.
6. Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91: 916-32.
7. Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17: 145-56.
8. Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45: 277-82.
9. Slattery ML, Ballard-Barbash R, Edwards S, et al (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14: 75-84.
10. Morimoto LM, Newcomb PA, White E, et al (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1204-11.
11. Slattery ML, Edwards SL, Ma KN, et al (1997) Physical activity and colon cancer: a public health perspective. Ann Epidemiol 7: 137-45.
12. MacMahon B, Trichopoulos D, Cole P, et al (1982) Cigarette smoking and urinary estrogens. N Engl J Med 307: 1062-5.
13. Newcomb PA, Storer BE, Marcus PM (1995) Cigarette smoking in relation to risk of large bowel cancer in women. Cancer Res 55: 4906-9.
14. Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106: 574-82.
15. La Vecchia C, Gallus S, Fernandez E (2005) Hormone replacement therapy and colorectal cancer: an update. J Br Menopause Soc 11: 166-72.
16. Leslie A, Carey FA, Pratt NR, et al (2002) The colorectal adenoma-carcinoma sequence. Br J Surg 89: 845-60.
17. Terry MB, Neugut AI, Bostick RM, et al (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11: 622-9.
18. Potter JD, Bostick RM, Grandits GA, et al (1996) Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 5: 779-84.
19. Morimoto LM, Newcomb PA, Ulrich CM, et al (2002) Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev 11: 1012-8.
20. Matthews KA, Kuller LH, Wing RR, et al (1996) Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 143: 971-8.
21. Barrett-Connor E (1991) Postmenopausal estrogen and prevention bias. Ann Intern Med 115: 455-6.
22. Sturgeon SR, Schairer C, Brinton LA, et al (1995) Evidence of a healthy estrogen user survivor effect. Epidemiology 6: 227-31.
23. Rossouw JE, Anderson GL, Prentice RL, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-33.
24. Anderson GL, Limacher M, Assaf AR, et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-12.
25. Newcomb PA, Storer BE (1995) Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87: 1067-71.
26. Kampman E, Potter JD, Slattery ML, et al (1997) Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 8: 146-58.
27. Pischon T, Lahmann PH, Boeing H, et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98: 920-31.
28. Slattery ML, Potter JD, Curtin K, et al (2001) Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61: 126-30.
29. Newcomb PA, Zheng Y, Chia VM, et al (2007) Estrogen plus progestin use and the risk of colorectal cancer in postmenopausal women cancer res 67:7534-9.
30. Chu KC, Tarone RE, Chow WH, et al (1995) Colorectal cancer trends by race and anatomic subsites, 1975-1991. Arch Fam Med 4: 849-56.
31. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Prevalence database: "US Estimated Complete Prevalence Counts on 1/1/2003". National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2006, based on the November 2005 SEER data submission.
32. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291: 47-53.
33. Slattery ML, Anderson K, Samowitz W, et al (1999) Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer. Cancer Causes Control 10: 467-73.
34. Mandelson MT, Miglioretti D, Newcomb PA, et al (2003) Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control 14: 979-84.
35. Murphy TK, Calle EE, Rodriguez C, et al (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152: 847-54.
36. Tamakoshi K, Wakai K, Kojima M, et al (2004) A prospective study of body size and colon cancer mortality in Japan: The JACC Study. Int J Obes Relat Metab Disord 28: 551-8.
37. Doria-Rose VP, Newcomb PA, Morimoto LM, et al (2006) Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). Cancer Causes Control 17: 63-70.
38. Gervaz P, Bouzourene H, Cerottini JP, et al (2001) Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44: 364-72.
39. Kim H, Jen J, Vogelstein B, et al (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145: 148-56.
40. Gryfe R, Kim H, Hsieh ET (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77.
41. Samowitz WS, Curtin K, Ma KN (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10: 917-23.
42. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-18.
43. Foley EF, Jazaeri AA, Shupnik MA, et al (2000) Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60: 245-8.
44. Fearon ER, Vogelstein B (1990) A genetic model of colorectal tumorigenesis. Cell 61: 759-67.
45. Morson BC (1974) Evolution of cancer of the colon and rectum. Cancer 34: 845.
46. McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65: 1201-7.
47. Reddy BS, Watanabe K, Weisburger JH, et al (1977) Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res 37: 3238-42.
48. McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3: 687-95.
49. Morimoto LM, Newcomb PA, White E, et al (2005) Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States). Cancer Causes Control 16: 917-27.
50. Heald A, Selby PL, White A, et al (2000) Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 183: 593-600.
51. Renehan AG, Wille-Jorgensen P (2004) Systematic review, Cochrane and Colorectal Disease. Colorectal Dis 6: 73-4.
52. Morimoto LM, Newcomb PA, White E, et al (2005) Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 14: 1394-401.
53. Bardin A, Boulle N, Lazennec G, et al (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537-51.
54. McDonnell DP, Norris JD (2002) Connections and regulation of the human estrogen receptor. Science 296: 1642-4.
55. Konstantinopoulos PA, Kominea A, Vandoros G, et al (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 39: 1251-8.
56. Potter JD, Cerhan JR, Sellers TA, et al (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4: 319-26.
57. Poutanen M, Isomaa V, Peltoketo H, et al (1995) Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol 55: 525-32.
58. Schairer C, Lubin J, Troisi R, et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-91.
59. Peterson CM (2000) Estrogen and progesterone receptors: an overview from the year 2000. J Soc Gynecol Investig 7: S3-7.
60. Di Leo A, Messa C, Cavallini A, et al (2001) Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 1: 1-12.
61. Baylin SB and Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joints genetics. Trends Genet 16: 168-74.
62. Issa JP, Ottaviano YL, Celano P (1994) Methylation of the oestrogen receptor CpG island link ageing and neoplasia in human colon. Nature Genet 7: 536-40.
63. Potter JD (1995) Hormones and colon cancer. J Natl Cancer Inst 87: 1039-40.
64. Hawkins N, Norrie M, Cheong K, et al (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376-87.
65. Whitehall VL, Wynter CV, Walsh MD, et al (2002) Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 62: 6011-4.